OTCPicks.com

FEATURED COMPANY

COPPER KING MINING CORPORATION (OTC: CPRK)

Detailed Quote: www.otcpicks.com/quotes/CPRK.php

Company Profile:
www.otcpicks.com/copper-king-mining/copper-king-mining.htm

Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.

CPRK News:

July 15 - Copper King Mining Corporation Announces Construction Updates

Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and Exploration company located in Southern Utah, today offered updates regarding its Floatation Mill’s construction near Milford Utah.

Copper King announced today that it awarded the bid to construct the substation that will supply power to the Copper King concentrator as part of its Floatation Mill construction to AF Electric. AF intends to begin work next week. Construction of the Master Control Center building has commenced and is targeted to be completed in 3 weeks. Placement of electric cable trays and heavy conduit inside the concentrator, which will provide power to the ball mills and cyclone deck, will begin this week also.

July 15 - Copper King Mining Corporation Offers Corporate Updates

Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and exploration company located in Southern Utah, provided updates concerning prior officers of Copper King Mining Corporation.

In response to shareholder inquiry, Copper King announced that neither Daryl nor Sandra Nether are Copper King officers, directors or insiders and are not involved in the company’s operations. Daryl and Sandra Nethers are Copper King shareholders. The company is in the process of updating its information on Pink Sheets.com in order to remove any incorrect, outdated, inaccurate or derogatory data. Pink Sheets.com is not a governmental regulatory entity but rather a private company that provides a forum to lodge information about companies listed on the Pink Sheet Exchange to the public.

FEATURED COMPANY

CELEBDIRECT INCORPORATED (OTC: CELI)
"Up 6.67% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CELI.php

Company Profile: http://www.otcpicks.com/celebdirect/celebdirect-2.htm

CelebDirect's primary business is that of a direct response celebrity incubator and has two divisions which are direct response marketing and Celebrity placement / franchise opportunities. CelebDirect brings to the market unique and innovative products via direct to market strategies such as infomercials, advertorials and other associated advertising vehicles to expeditiously, economically and broadly market products throughout North American as well as a global basis. CelebDirect has a number of consumer-oriented products it is evaluating and others it is currently bringing to market.

CELI News:

July 15 - CelebDirect Inc. Rated 'Speculative Buy' Target Price $0.31 by Beacon Equity Research

CelebDirect Inc. (OTC: CELI) has been rated Speculative Buy with a price target of $0.31 by Beacon Equity Research Analyst, Victor Sula, Ph.D.

The full report is available at www.BeaconEquity.com/reportsonline/CELI.

In the report, the analyst writes, "CELI is pursuing an aggressive growth strategy in the fitness equipment market with the goal of garnering meaningful market share and a national presence ... The Company has begun the first phase of its direct response marketing strategy for the Muscle Flex(TM) in the second half of July 2008, in a number of Martial Arts and Mixed Martial Arts publications and online Web sites."

Other companies in the product marketing industry include Callaway Golf Co. (NYSE: ELY), Nautilus Inc. (NSYE: NLS), Cybex International Inc. (Nasdaq: CYBI) and Johnson Outdoors Inc. (Nasdaq: JOUT).

FEATURED COMPANY

WIND ENERGY AMERICA INCORPORATED (OTCBB: WNEA)

Detailed Quote: www.otcpicks.com/quotes/WNEA.php

Company Profile:
www.otcpicks.com/wind-energy-america/wind-energy-america-2.htm

Wind Energy America Inc. develops and operates wind energy projects in the Great Plains and the Midwest, regions known for their high quality wind energy resources. The Company owns interests in three wind farms: Shaokatan Hills LLC, Lakota Ridge LLC and CHI Energy. At present, WNEA owns a developer's stake and a minimal interest producing negligible cash flow in these wind farms. Over the next two years the developer’s stake will begin producing significant cash flow from these projects. The three wind farms together contain 79 modern wind turbines and have a total rated capacity of 53.5 megawatts (MW). They are collectively generating approximately 160 million kilowatt hours (kWh) of electricity annually. In addition to these properties, the Company owns a 3 percent equity interest in Averill Wind LLC, a 10 MW wind farm being developed near Fargo, N.D., another region favorable for wind power energy.

WNEA News:

July 15 - Wind Energy America Inc. Rated 'Buy' by BrokerBank Securities

Wind Energy America Inc. (OTCBB: WNEA) has been rated a “Buy” by BrokerBank Securities’ Philip Wright, CFA.

The full report is available via download at https://brokerbanksecurities.com.

In the report, the analyst writes, “Boreal assets purchased by the Company included Boreal’s interests and development rights to various wind farm projects in the Upper Midwest and Great Plains regions and located in some of the most favorable wind regimes in North America for generation of electricity from wind power turbines. This extensive “pipeline” of wind power projects includes approximately 1,200 megawatts of rated turbine power capacity in various phases of design or development. WNEA shares are a BUY. These shares could triple in 12 months.”

FEATURED COMPANY

XSUNX INCORPORATED (OTCBB: XSNX)

Detailed Quote: http://www.otcpicks.com/quotes/XSNX.php

Company Profile: http://www.otcpicks.com/xsunx/xsunx.htm

Xsunx, Inc., a thin-film photovoltaic (TFPV) company, focuses on developing thin film photovoltaic (TFPV) amorphous silicon solar cell manufacturing processes to produce TFPV solar modules. Its product includes XsunX ASI-120 module, which is a 125 peak watt TFPV solar module utilizing glass substrates and a proprietary semiconductor manufacturing system. XsunX ASI-120 provides for a module delivering high power output, and size and framing that would allow for the use of various existing mounting systems. The target markets for the TFPV solar module include solar farms, government agencies, and utility companies, as well as power purchase agreements and large commercial installations worldwide. The company, formerly known as Sun River Mining, Inc., was incorporated in 1997 and changed its name to XsunX, Inc. in 2003. XsunX is headquartered in Aliso Viejo, California.

XSNX News:

July 14 - XsunX to Present to Financial Communities in Chicago, New York, Boston and Atlanta

XsunX, Inc. (OTCBB: XSNX), a solar technology Company engaged in the build-out of its multi-megawatt thin film photovoltaic (TFPV) solar manufacturing facilities, announced that Company CEO Tom Djokovich will begin a series of meetings with members of the financial communities in Chicago, New York, Atlanta and Boston during July and August. Additional meetings on the West Coast will take place during the month of September.

In these meetings Djokovich will outline the Company's progress as well as its outlook for the coming months as the company works to complete the installation of its base production infrastructure in Portland, Oregon in 2008 and then grow capacities to 25MW by 2009 and 100MW by 2010.

Further information on the meetings may be obtained by contacting Beverly Jedynak at 312-943-1123 or This email address is being protected from spam bots, you need Javascript enabled to view it to make a reservation as space at these meetings are limited and reservations must be made in advance.

FEATURED COMPANY

MONOGRAM ENERGY INCORPORATED (OTC: MGRN)

Detailed Quote: www.otcpicks.com/quotes/MGRN.php

Company Profile:
www.otcpicks.com/monogram-energy/monogram-energy.htm

Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production.

MGRN News:

July 14 - Monogram Energy Inc. Negotiates New Lease

Monogram Energy Inc. (OTC: MGRN) announced that it has begun negotiations to acquire a 25% working interest in a well in the Mayfield lease in Brisco County, Texas. In 1982, Marathon Oil drilled the well, and at the time of drilling, the well tested at 132 barrels per day at 7,900 feet, with a porosity of 42%. Current production on the well is 2-3 barrels per day, due to clogging by lost circulation material. To alleviate the slowdown, laterals will be drilled to increase the potential production to 80-90 barrels per day. Workover costs are estimated to be $200,000.

Mr. Billy King, Chief Executive Officer of Monogram Energy, Inc., stated, "We think this well has tremendous potential. If we can get close to the projected production, we'll have a quick payback on our investment."

Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders.

FEATURED COMPANY

LANTIS LASER INCORPORATED (OTC: LLSR)

Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php

Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm

Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System™ in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.

LLSR News:

July 15 - Lantis' OCT Dental Imaging System Featured in Report on Light-Based Diagnostic Modalities for Early Decay

Lantis Laser Inc. (OTC: LLSR) (www.lantislaser.com) issued a statement drawing attention to a recent significant report on a leading professional dental website, www.DrBicuspid.com, highlighting the status of light-based diagnostic modalities for the early detection of decay.

Early detection of decay is an important part in the practice of minimally invasive dentistry and the “medical model” of finding disease early and treating it early with topical or chemical means to avoid surgical intervention.

Lantis' OCT Dental System is addressed in Part III.

The report was published on the Internet in three parts, with the last, Part III, titled:

"Beyond x-rays: Part III — OCT brings early decay to light" www.drbicuspid.com/index.aspx?sec=sup&sub=img&pag=dis&ItemID=300735&wf=34

Links to Part I and Part II, which discuss currently available diagnostic products, are accessible at the end of Part III.

Lantis' OCT Dental Imaging System is based on novel, light-based bio-medical imaging technology, Optical Coherence Tomography (OCT), that enables the dentist to do diagnostic imaging, chairside and in real-time. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects. As the power source is light-based, unlike x-ray there is no harmful radiation.

STOCKS TO WATCH

LEV PHARMACEUTICALS (OTCBB: LEVP)
"Up 29.46% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/LEVP.php

Lev Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops and commercializes therapeutic products for the treatment of inflammatory diseases. It develops Cinryze (C1 inhibitor), which is a replacement therapy for the acute and prophylactic treatment of hereditary angioedema, also known as C1 inhibitor deficiency characterized by episodes of edema in the extremities, face, abdomen, and airway passages. The company's products also include C1-INH intended for the treatment of other diseases and disorders, such as acute myocardial infarction or heart attack. It has a strategic alliance with Sanquin Blood Supply Foundation. The company was founded in 2003 and is based in New York, New York.

LEVP News:

July 15 - ViroPharma to Acquire Lev Pharmacueticals

* Acquisition Adds Late Stage Product Targeting Life-threatening Hereditary Angioedema Disease with Limited Treatment Options
* Companies to Host Conference Call at 10:30 A.M Eastern Today to Discuss Transaction

ViroPharma Incorporated (NASDAQ: VPHM) and Lev Pharmaceuticals, Inc. (OTCBB: LEVP) announced that the companies have signed a definitive merger agreement under which ViroPharma will acquire Lev, a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases, for $442.9 million of upfront consideration, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock (subject to a collar). Contingent consideration of up to $1.00 per share may be paid on achievement of certain regulatory and commercial milestones. The transaction with a potential net aggregate value of up to $617.5 million has been unanimously approved by the boards of directors of both companies. The companies expect the transaction to be completed by the end of 2008. In addition, concurrently with the execution of the merger agreement, ViroPharma purchased $20 million of Lev common stock.

The acquisition of Lev Pharmaceuticals further enhances ViroPharma’s pipeline with Cinryze™ (C1 inhibitor (human)), which is currently under regulatory review for approval by the U.S. Food and Drug Administration as a replacement therapy for patients with hereditary angioedema (HAE), also known as C1 esterase inhibitor (C1-INH) deficiency. The use of replacement therapy in patients with C1-INH deficiency is supported by more than 35 years of clinical practice experience in Europe. C1-INH depletion is also implicated in a number of other serious inflammatory disorders.

Hereditary angioedema, or C1-INH deficiency, is a dangerous and potentially deadly inflammatory disease affecting up to 10,000 patients in the United States, caused by a genetic deficiency in an essential protein called C1 esterase inhibitor. Clinical studies have shown that prophylactic C1 inhibitor replacement therapy with Cinryze can significantly reduce the severity, duration and frequency of HAE attacks.

“This transaction is consistent with ViroPharma’s stated objective of broadening our portfolio of therapies for serious life-threatening conditions in selected specialty markets,” commented Vincent Milano, ViroPharma’s president and chief executive officer. “Lev’s orphan drug Cinryze™ is a life-saving therapy treating a very dangerous disease. This opportunity provides a clear strategic fit with ViroPharma: Cinryze targets a market that is addressable with modest additional infrastructure and further serves patients suffering from a disease with few treatment options. We are very pleased to add the expertise of Lev to our organization, and Cinryze to our growing portfolio of options for underserved patient populations with critical and urgent needs.”

“We believe this transaction recognizes the value we have created at Lev and provides our shareholders with attractive financial terms, through the upfront payment and the opportunity to continue to share in the success of Cinryze™ through the ownership of ViroPharma shares and the contingent value rights,” commented Judson Cooper, Lev’s chairman of the board. “Leveraging the combined resources of both companies not only strengthens our C1 inhibitor development platform, but also underscores our commitment to serving patients with critical unmet medical needs.”

Transaction Terms

Under the terms of the merger agreement, ViroPharma will acquire the outstanding common stock of Lev for $2.25 per share in cash and $0.50 per share in stock (“Upfront Consideration”), subject to a collar. The Upfront Consideration value could be lower or higher if the ViroPharma average common share price is lower than $10.03 or higher than $15.68 per share during the twenty trading day period prior to closing. In addition, Lev shareholders will receive the non-transferrable contractual right to two contingent payments (“CVR Payments”) of $0.50 each that could deliver up to an additional $174.6 million, or $1.00 per share in cash, if the Company meets certain targets. The first CVR payment of $0.50 per share would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party’s human C1 inhibitor product for two years from the later of the date of closing and the date that orphan exclusivity for Cinryze for the prophylaxis of HAE becomes effective. The second CVR payment of $0.50 per share would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing. The Upfront Consideration of $2.75 per share and the potential for a total value of $3.75 per share represent premiums of 49% and 103%, respectively, over Lev’s closing stock price on July 14, 2008.

Closing is subject to certain conditions including approval under the Hart-Scott-Rodino Act, the approval of Lev’s shareholders and other customary closing conditions. Mr. Judson Cooper, Lev’s chairman of the board, and Dr. Joshua Schein, Lev’s chief executive officer, respectively, and their affiliates, who collectively hold an aggregate of approximately 23% of the outstanding Lev shares, have agreed to vote their shares in favor of the transaction.

Additionally, ViroPharma agreed to make a $20 million investment in Lev, at signing, by purchasing 9,661,836 shares of Lev common stock at a 10 percent premium to the five day average closing price of Lev’s shares for the period ending Friday, July 11, 2008, sold pursuant to Lev’s effective registration statement on Form S-3.

J.P. Morgan Securities Inc. advised ViroPharma and DLA Piper acted as legal counsel. In addition, Piper Jaffray & Co. provided a fairness opinion to ViroPharma’s board of directors. J.P. Morgan Securities Inc., as successor to Bear, Stearns & Co. Inc., advised Lev and provided a fairness opinion to Lev’s board of directors. Willkie Farr & Gallagher LLP and Becker & Poliakoff, LLP acted as legal counsel to Lev.

Cinryze™ Regulatory Status

On May 2, 2008, the Blood Products Advisory Committee (BPAC) to the U.S. Food and Drug Administration (FDA) voted unanimously that there is sufficient evidence of the safety and efficacy for the approval of Cinryze for the prophylactic treatment of HAE. The data from Lev's acute treatment trial was not presented before the BPAC and is currently under active review at FDA. On May 6, 2008, Lev announced that FDA accepted for review Lev's complete response submission for Cinryze targeting an action date of October 14, 2008.

ABOUT HEREDITARY ANGIOEDEMA

HAE is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. While there is no approved therapy for acute HAE attacks in the U.S., a commercially available C1 inhibitor has been used in Europe to treat HAE for more than 35 years. There are estimated to be 10,000 people with HAE in the U.S.

Additional information on HAE can be obtained from the U.S. Hereditary Angioedema Association at www.haea.org.

ABOUT VIROPHARMA INCORPORATED

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at www.viropharma.com.

NPI08 INCORPORATED (OTC: NPIA)
"Up 90.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/NPIA.php

NPI08, Inc. provides products and information services to students and their families, which assist them in the college preparation process. The company offers assistance in career planning, college major/field of study selection, college selection, preparation for college entrance tests, and searches for merit awards and financial aid, as well as aids for improving study skills. In addition, it provides services to promote students for athletic scholarships to prospective colleges and universities. NPI08’s products consist of printed materials, videocassettes, college major/field of study software, career assessment software, databases accessible through compact disk read only memory, and one-to-one coaching. It markets its products primarily through weekend workshops held throughout the United States, as well as through its direct sales force and Web site. The company was founded by Janice A. Jones and John J. Grace. The company was formerly known as Sports Star Marketing, Inc. and changed its name to College Bound Student Alliance, Inc. in 1999. Further, it changed its name to College Partnership, Inc. in 2003 and to NPI08, Inc. in February 2008. The company is headquartered in Lakewood, Colorado. On July 30, 2007, a group of creditors, including Global Capital Associates, Inc. filed an involuntary petition for liquidation under Chapter 7 against College Partnership Inc. in the U.S. Bankruptcy Court for the District of Utah, Salt Lake City.

NPIA News:

July 14 - Infinity Capital Group, Inc. Acquires Controlling Interest in NPI08, Inc.

Infinity Capital Group, Inc. announced that it has closed the acquisition of approximately 87.5 percent of the issued and outstanding shares in NPI08, Inc. (OTC: NPIA) ("the Shares") after the Denver Federal Bankruptcy Court approved the sale. The consideration for the transaction included a combination of cash, Infinity common stock, and a promissory note to the Sellers collateralized with the Shares pending payment.

Infinity intends to utilize its controlling ownership to facilitate a reverse merger between NPIA and a privately held, growth-oriented operating business that is seeking to access capital and a public market. Upon consummating the NPIA share purchase, Infinity CEO Greg Laborde stated, "In today's capital markets, where access to public capital and liquidity options for small companies are limited, we are pleased to have taken control of another vehicle which will enable us to help a thriving privately held company to grow and expand while providing their current owners potential liquidity." Mr. Laborde continued, "We see access to public capital as a vital service to growing companies who are the engine for overall economic growth and see tremendous opportunity for Infinity to earn attractive investment returns while facilitating this important capital formation need."

Infinity intends to make a follow on investment in NPIA in connection with the reverse merger and as part of its mission as a business development company it will provide management assistance in connection with and post closing the merger. The NPIA plan is similar to Infinity's January 2008 transaction where it facilitated a reverse merger between a controlled publicly traded subsidiary and two related privately held growth companies, REGS, LLC and Tactical Cleaning, LLC — creating the Infinity portfolio company Strategic Environmental & Energy Resources, Inc. (OTC: SENR). In connection with the SENR transaction, Infinity invested its own capital and assisted the company in attracting additional investment from other sources.

Infinity targets privately held emerging growth companies, across a broad range of attractive industries, with revenues of US$5-$15 Million, whose growth is constrained by limited capital. Infinity seeks companies with strong management teams that are at or near profitability and have the potential to list on a National Exchange within 12-18 months. In a typical transaction, Infinity will provide long term capital, primarily via equity investments, and as a business development company Infinity provides managerial assistance throughout the process and post closing of the transaction. Its mission is to offer entrepreneurial businesses a viable financing alternative to traditional private equity and venture capital funds that generally insist on control while also providing the incumbent business owners with personal liquidity and a potential exit strategy.

In addition to target merger candidates, Infinity is seeking controlling interest in public companies looking to change strategy, that have sold or closed a business and whose shareholders will participate in a subsequent transaction.

ABOUT INFINITY CAPITAL GROUP, INC.

Infinity Capital Group is a business development company that provides early-stage or mezzanine financing and management assistance to emerging growth companies. The company typically invests in companies that intend to go public through an IPO or by a reverse merger with an already public firm. It also funds small public companies that are undergoing significant change in strategy. Investments by Infinity are not limited to any particular industry.

HALL OF FAME BEVERAGES INCORPORATED (OTC: HFBV)
"Up 5.88% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/HFBV.php

Hall of Fame Beverages, Inc. engages in the creation, manufacture, distribution, and marketing of non-alcoholic beverages. Its products include Atomic Dogg energy drink; and a line of enhanced flavored waters to provide refreshment and hydration, as well as the replacement of vital minerals and vitamins under the HydroPower brand. The company also intends to offer Grandmama's sweet southern tea. It was formerly known as OG Nation, Inc. and changed its name to Hall of Fame Beverages, Inc. in March 2008. The company is based in Gilbert, Arizona.

HFBV News:

July 15 - Hall of Fame Beverages, Inc. Announces Licensing of Popular George Clinton Song, Atomic Dog

Hall of Fame Beverages, Inc. (OTC: HFBV) announced that they have licensed for commercial use the widely popular hit song “Atomic Dog” by George Clinton. The iconic and classic hit song “Atomic Dog” transcends both cultural and demographic divides worldwide and is one of the most influential and recognized dance songs in the history of both Pop and Urban music.

CEO Robert Rosario states, “I am thankful to Bridgeport Music Inc. (BMI), Southfield Music Inc. (ASCAP), and George Clinton for allowing us to continue in the grand entertainment tradition of the P-FUNK through our Atomic Dogg energy drink.”

Mr. Rosario adds, “The song ‘Atomic Dog’ will be instrumental in spearheading our roll out Marketing and Advertising campaign for the brand. It will be an integral component in telling our Atomic Dogg story in our radio/internet, and television advertising campaigns. The song combined with our promotional material I believe is going to create excitement at retail along with instant brand awareness with our core demographic and the general market as well.”

“I am very excited about our Atomic Dogg marketing campaign,” added Calvin Ross, COO of HFBV. “Along with being a great song that bears the name of our drink, it will also give us tremendous brand recognition and credibility with our target market.”

Both Robert Rosario and Calvin Ross will be begin a 5 city trip next week to meet with media, radio stations, and promotion companies to start the Atomic Dogg advertising awareness campaign. To view the Atomic Dogg Promotional Campaign and listen to the first of Atomic Dogg radio commercials go to the newly created MySpace page at www.myspace.com/atomicdoggenergy.

SYNTHEMED INCORPORATED (OTCBB: SYMD)
"Up 34.62% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SYMD.php

SyntheMed, Inc., a biomaterials company, engages in the development and commercialization of medical devices for therapeutic applications. It offers surgical implants designed to prevent or reduce the formation of adhesions/scar tissue following a range of surgical procedures. The company's lead product includes REPEL-CV, a bioresorbable film designed to be placed over the surface of the heart at the conclusion of surgery to reduce the formation of post-operative adhesions. SyntheMed offers products based on the proprietary, bioresorbable polymer technology. Its products also include REPEL-AFIB, which reduces the patient risk associated with atrial fibrillation; RESOLVE that prevents or reduces post-operative surgical adhesions in gynecological and general abdominal surgery; and RELIEVE for preventing or reducing post-operative surgical adhesions in orthopedic and spinal surgery. The company, formerly known as Life Medical Sciences, Inc., was founded in 1990 and is headquartered in Iselin, New Jersey.

SYMD News:

July 14 - SyntheMed Receives Canadian Approval for REPEL-CV®

SyntheMed, Inc. (OTCBB: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced that REPEL-CV®, the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart surgery. REPEL-CV will be marketed throughout Canada by Force3 Medicale, Inc., a Montreal-based distributor of cardiac surgery products. Marc Sportsman, SyntheMed's Vice President of Sales, stated, "We are pleased to receive the Health Canada approval which allows us to further expand the international distribution of REPEL-CV."

SyntheMed was previously granted CE Mark approval to market REPEL-CV in most international markets for use in all patients who undergo open heart surgery and is being sold through a network of independent distributors. In November 2007, SyntheMed received an Approval Letter from the US FDA stating the REPEL-CV would be approved for use in pediatric patients pending satisfactory completion of field inspections. This process is ongoing as are discussions with the FDA on the requirements for expansion of the indication for REPEL-CV from pediatric patients to all patients who undergo cardiac surgery.

ABOUT ADHESIONS

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure.

ABOUT REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions (scar tissue) that form between the surface of the heart and opposing tissue surfaces following the surgical procedure. REPEL-CV is designed to provide the therapeutic benefit and then degrade so that it is cleared from the body. REPEL-CV represents the first in a series of anti-adhesion products under development that are based on the Company's proprietary polymer technology.

CHINA RUNJI CEMENT INCORPORATED (OTCBB: CRJI)
"Up 25.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CRJI.php

Founded in 2003, China Runji Cement, Inc. is one of the leading players in cement production and distribution. In October 2007, the Company became a U.S. public company following the completion of a share exchange with Fitmedia Inc. The Company's certified manufacturing facilities contain cutting-edge technology and advanced equipment and are capable of producing as much as 1 million tons of cement annually. Furthermore, the Company's solid distribution network and customer-oriented services have earned Runji's products a superior reputation among its customers. Headquartered in Anhui Province, the Company's markets include major local cities such as Hefei, Nanjing, and Liu'an. For more information on the Company and its products, visit www.chinarunji.com/index.asp.

CRJI News:

July 15 - China Runji Cement Inc. Reports Third Quarter and Nine Month Results

China Runji Cement Inc. (OTCBB: CRJI) (“Runji” or “the Company”), a leading cement manufacturing and distribution company headquartered in Anhui Province, People's Republic of China (“PRC”), announced its results for the third quarter and nine months ended May 31, 2008.

2008 Key Financial Highlights:

* Revenues for the three months ended May 31, 2008 were $11.68 million, up 101% from the same period last year. For the nine months ended May 31, 2008, revenues were $27.9 million, up 39% from $20.1 million for the same period last year.

* Gross profit for the three months ended May 31, 2008 was $2.86 million, up 874% from $0.29 million for the same period last year.

* Gross profit for the nine months ended May 31, 2008 was $6.3 million, up 214% from $2 million for the same period in 2007.

* For the three months ended May 31, 2008 gross margin increased to 24.5% from 4.9% for the same period last year. Gross margin for the nine months ended May 31, 2008 was 22.6%, compared with 9.9% of the same period last year.

* Net income for the three months ended May 31, 2008 was $2.69 million, or $0.03 per fully diluted share, compared with net loss of $(2,449) in the same period last year. Net income for the nine months ended May 31, 2008 increased 1811% to $4.97 million, or $0.07 per fully diluted share, from $0.26 million, or $0.00 per fully diluted share, of the same period in 2007.

“We are glad to achieve a substantial increase in revenue and net income. In particular we are excited to see a significantly higher margin in the third quarter,” said Mr. Shouren Zhao, Chairman & CEO of China Runji Cement Inc. “Over the past quarter, we have overcome the negative effects imposed from overwhelming weather conditions in the second quarter and are back to normal production capacities. In light of the strong market demand and sales price hike in cement industry, we are confident to maintain an expanding margin in the coming quarter. Furthermore, our second cement clinker production line will come online in October, which will substantially increase our production capacity and generate more revenue. We are committed to maintain the best production status to capture the strong market demand.”

Third Quarter Fiscal Year 2008 Results

Revenues for the three months ended May 31, 2008 increased by $5,872,213 or 101% to $11,681,719 from $5,809,506 for the same corresponding period in 2007. The increase is primarily attributed to increased sales volume, especially PO42.5 cement, and also due to retail price hike for cement products.

Of the $11,681,719 in revenue for the three months ended May 31, 2008, approximately $8,435,168 (or 72%) was generated from sales of PO42.5 cement, and $453,022 (or 4%) from the premium grade cement PII52.5.

Our gross profit increased by $2,568,446 or approximately 874% to $2,862,188 for the three months ended May 31, 2008 from $293,742 for the same period in 2007. The increase primarily resulted from the increase in the retail price of cement products in China. This increase counter balanced the negative effect imposed by the increase in raw material costs. We are able to transfer the costs of raw materials to our customers by increasing the retail price of cement.

Net income for the third quarter of 2008 was $2.69 million, or $0.03 per fully diluted share, up from net loss of ($2,449), or $0.00 per fully diluted share, in the third quarter of 2007. Net margin for the period grew to 23% from 0.0% in third quarter 2007.

Financial Condition

For the nine months ended May 31, 2008, the Company had $2.2 million in cash and cash equivalents, ($4.6) million in working capital and a current ratio of 0.62. Runji had $0.4 million in short-term loans payable and $19.6 million in shareholders' equity. The Company's cash flows from operations in the nine months of financial year 2008 were $9.3 million. To date, Runji has funded most of its cash needs with loans from related parties, which totaled $28.4 million as of May 31, 2008.

Business Outlook

As the cement demand and market price are growing quickly in China, Runji's operation has experienced high growth in the third quarter. Furthermore, Anhui's annual growth rate of 11%, which is above the national average, has translated into an abundance of construction projects, particularly large-scale government sponsored infrastructure projects which is demanding in cement quality.

“Our current cement clinker output is 2,500 tons per day and our production facilities are operating in full capacity,” said Mr. Zhao. “Our second cement production line with same capacity is expected for trial production next month and will be put in full production in October. Furthermore, we are also building a waste heat power generator which will come online in 2009, which will generate electricity of around 63 million KW annually and further reduce our operating costs and increasing margins.”

Current Capacity:

* Currently have one cement clinker production line with designed capacity of 2,500 tons per day or 775,000 tons per year.

* Has been producing at around 120% capacity in the past two years to meet with the high cement demand.

* The second production line with 2,500 tons daily output will come online in October 2008. Cement clinker designed capacity of the Company will be doubled to 1.5 million ton per year upon completion.

MYECHECK INCORPORATED (OTCBB: MYEC)
"Up 19.05% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MYEC.php

MyECheck Inc. is a leading electronic transaction processor and provider of alternative payment solutions to credit cards for brick & mortar, internet, and intranet commerce. MyECheck utilizes a proprietary method of creating and clearing remotely created checks (RCCs) for exceedingly fast, secure and convenient payments. As the leader in Check 21 solutions and check image processing for online merchants, MyECheck's patented RCC solution provides merchants with financial access to more consumers than any other single payment method. Visit www.myecheck.com for more information.

MYEC News:

July 15 - MyECheck Inc. Patented Software Goes Live With Mentor Public Schools

Check 21 Processor Implements in Ohio School District

MyECheck Inc. (OTCBB: MYEC), an electronic transaction processor and provider of alternative payment solutions, announced that its software has gone live at Mentor Public Schools, an Ohio School District.

MyECheck previously announced that an agreement had been signed and managed to implement its software within about 5 days of the signing. This quick turn-around is attributed to the streamlined integration process that MyECheck has now built for its clients utilizing easy application programming interfaces (APIs).

Ed Starrs, CEO of MyECheck, commented, "Our APIs have evolved with the changing needs of our clients to the point where we can have a customer 'live' within a week of bank interface approval. We will continue to streamline this process and work with both our internal team and outside VARs to ensure that we provide a cutting-edge technology in this growing industry."

Mentor Public Schools is a School District in Mentor, Lake County, Ohio with 14 schools, including elementary, middle and high schools. MyECheck's eCheck solution now provides parents with the option of debiting their checking accounts for payments such as loading their children's lunch cards safely as an example.

BIONIC PRODUCTS INCORPORATED (OTC: BNPD)
"Up 25.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BNPD.php

Bionic-Tonic and LadyPink are refreshing energy drinks providing an increase in energy without the calories and sugar. Our products contain the finest ingredients available to assist metabolic levels and burn calories. The power and energy drink along with shot size boosters business is one of the fastest growing sectors in the entire beverage industry. Bionic Products, Inc. is a Nevada Corporation formed for the purpose of discovering, developing and marketing breakthrough energy drinks and bottled water that will enhance the health and wellness of consumers. The company's common stock is traded on the OTC under the symbol "BNPD." For more information or a copy of Bionic's research report, visit www.bionicproducts.us or www.myotctrader.com as Bionic Products will have a full feature in this new and promising informative internet site.

BNPD News:

July 15 - BPI in Negotiations With Established Network Marketing Group for 'Bionic-Tonic' and 'LadyPink' Natural Energy Drinks

Bionic Products, Inc. (OTC: BNPD) announced that the company is in negotiations with an established California "Networking Marketing Group" for "Bionic-Tonic" and "LadyPink" all natural energy drinks.

A Bionic Products spokesman commented, the negotiations are going extremely well and if the two companies reach a satisfactory settlement this week, product could be shipping to end users by the end of the month. This is a major boost for market awareness of the company's natural energy drinks.

The Network Marketing Industry is one of the largest Multi-Billion Dollar retail market awareness opportunities in the World, with a multitude of products being delivered daily to millions of end users on a daily basis. The revenues segment of the Energy Drink Industry according to industry consulting firm Beverage Marketing — Energy drink sales have increased nearly 700 percent since 2001 and account for $5.6 billion domestic market. This product genre is popular among nearly all demographics, but is especially popular among the teen, 20- and 30- something age brackets. Why? In a word, convenience. "Functionally speaking, the key driver behind the growth of this market is the convenience and popularity of energy drinks as a functional delivery system," according to a December 2007 consumer report by Packaged Facts.

Since the first scheduled production run of the company's products earlier this month, the response from the Las Vegas Club Scene and entertainment industry has been very encouraging stated, J. D. Pulver, Bionics Vice President & Director of Marketing. The accelerated interest from the California based Network Marketing Group has encouraged the company to increase production of the third quarter product run to satisfy the anticipated sales from the Network Marketing Program.

DELPHI CORPORATION (OTC: DPHIQ)
"Up 31.25% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DPHIQ.php

Delphi Corporation supplies vehicle electronics, transportation components, integrated systems and modules, and other electronic technologies primarily in North America and Europe. Its Electronics and Safety segment offers controls and security products that consist of body computers, security systems, displays, and mechatronics; entertainment and communications products, including advanced reception systems, digital receivers, satellite audio receivers, navigation systems, rear-seat entertainment, and wireless connectivity products; safety systems, such as airbags, occupant detection systems, collision warning systems, advanced cruise control technologies, safety electronics, seat belts, and steering wheels; and power electronics that include power modules, inverters and converters, and battery packs. The company's Powertrain Systems segment provides products for engine management systems; diesel EMS product line that offers rail system technologies; fuel handling systems for gasoline, diesel, flexfuel, and biofuel configurations; and emissions systems. Its Electrical/Electronic Architecture segment offers electrical/electronic distribution systems, connection systems, and electrical centers. The company's Thermal Systems segment offers radiators, condensers, and charge air cooling heat exchangers; and climate control products, including HVAC modules, compressors, and controls. Delphi's Automotive Holdings Group segment provides suspension components and brake components. The company was founded in 1998 and is headquartered in Troy, Michigan. On October 8, 2005, Delphi Corporation along with its affiliates jointly filed a voluntary petition for reorganization under Chapter 11 of the US Bankruptcy Court for the Southern District of New York. Delphi Corp. operates independently of General Motors Corporation as of May 28, 1999.

DPHIQ News:

July 14 - Delphi Retains W.Y. Campbell & Company to Coordinate Sale Process for Brake Business

Delphi Corp. (OTC: DPHIQ) announced the retention of W.Y. Campbell & Company to explore sale opportunities for Delphi's Brake business.

Delphi's Brake business has estimated 2008 revenue of $295 million and provides fully integrated brake system solutions to customers as well as engineered components tailored to customer requirements.

Delphi's Brake business has more than 1,000 employees globally throughout three manufacturing and assembly facilities located in Juarez, Mexico and Shanghai, China. The business also has technical centers in Shanghai, China; Brighton, Michigan; and Dayton, Ohio.

Parties interested in Delphi's Brake business should contact, Cliff Roesler, Managing Director, W.Y. Campbell & Company at 313.496.9000 or This email address is being protected from spam bots, you need Javascript enabled to view it .

For more information about Delphi, visit www.delphi.com.